USF scientists have designed a novel compound class that shows promise to specifically target the anti-apoptotic Bcl-2 family of proteins, particularly Bcl-xL, without damaging healthy cells. The majority of human cancers over-express Bcl-xL and Bcl-2. These proteins not only contribute to cancer progression, but render cancer cells resistant to cancer treatment. Our scientists have designed sulfonamide based compounds which have been successful in disrupting Bcl-xL-protein interactions. This novel approach could change the face of standard cancer-care.
Natural Protein Bak (green) Binds to Target Protein Bcl-xL (yellow). Lead Compounds Disrupt the Bcl-xL-Bak Interactions and Trigger Apoptosis in Cancer Cells.